Active Pharmaceutical ingredient (API)

1. Active Pharmaceutical Market Leadership An active pharmaceutical ingredient (API) is a drug or a combination of drugs used in finished pharmaceutical products (FPP) intended for the diagnosis, treatment, or prevention of diseases. API is the component of any drug that produces the intended effects. Some drugs, such as combination therapies, have multiple active ingredients to treat different symptoms or act in different ways. Production of APIs has conventionally been done by pharmaceutical companies in their home countries; however, in recent years, many companies have chosen to send manufacturing overseas with an aim to cut costs. This has caused major changes in how these drugs are regulated, with more stringent guidelines and inspections put into place. 360Quadrants, the most granular comparison platform, has released a quadrant on the Active Pharmaceutical Ingredient Market to help businesses make quicker and more informed decisions. The quadrant has Pfizer, Roche, and Sanofi sharing space as Visionary Leaders. 360Quadrants are generated Active Pharmaceutical Ingredient Leaders Like product maturity and company maturity. Quadrants will be updated every three months based on market and regional analyses and developments in the Active Pharmaceutical Ingredient Market. 360Quadrants also lists the 20 best companies in the Active Pharmaceutical Ingredient Market space. Get Sample PDF (including COVID19 Impact Analysis) of Market Report @ https://www.360quadrants.com/quadrant-report/active-pharmaceutical-ingredient-(api)/buy- now?reporttype=corporates_license_price CATEGORIZATION OF ACTIVE PHARMACEUTICAL INGREDIENT (API) VENDORS ON 360QUADRANTS 30+ companies offering Active Pharmaceutical Ingredients were analyzed, of which 20 Top Active Pharmaceutical Ingredient companies were shortlisted and categorized on a quadrant under Visionary Leaders, Innovators, Dynamic Differentiators, and Emerging Leaders. Pfizer, Roche, Sanofi, Novartis, AbbVie, GlaxoSmithKline, Gilead Sciences, Merck & Co, Eli Lilly, Johnson & Johnson, AstraZeneca, Celgene, and Boehringer Ingelheim have been identified as Visionary Leaders,as they have established product portfolios and a robust market presence &business strategy. Teva, Allergen, Amgen, and Bristol-Myers Squibb have been identified as Innovators, as they have focused product portfolios but mediocre business strategies. Novo Nordisk, Mylan, and Biogen Idec have been recognized as Dynamic Differentiators, as they have strong business strategies but weaker product offerings as compared to other market players. These companies are known to focus on specific product offerings, as opposed to having elaborate portfolios. Takeda, Daiichi Sankyo, Shire, and Astellas have been identified as Emerging Companies, as they have niche product offerings but poor business strategies. 360Quadrants conducts an in-depth SWOT analysis and accurately analyzes the companies considered for evaluation. This helps service providers learn about new opportunities and areas where they lag behind their peers. It also helps clients choose the most appropriate vendors for their

2. requirements. GlaxoSmithKline (UK) is one of the key players in the global API market. The Pharmaceuticals segment of the company has a broad portfolio of innovative and established medicines. GSK focuses on research &development activities, which gives the organization a competitive advantage. For instance, the company invested significantly in R&D activities in 2018 and 2019. Moreover, the R&D activities undertaken by the company aim at incorporating genetics and advanced technologies. The company is involved in the contract manufacturing of APIs in Ireland, the UK, Singapore, and Australia. The company primarily focuses on collaborations and partnerships to enhance its product offerings and maintain its position in the market. Buy (Global) Company Evaluation Report https://www.360quadrants.com/quadrant-report/active- pharmaceutical-ingredient-(api)/buy-now?reporttype=corporates_license_price Bristol-Myers Squibb (US) is a prominent player in the API market and holds expertise in pharmaceutical ingredients. The company has a broad product portfolio in biologics, which isan important factor inits future growth, especially in the biopharmaceuticals market. The company invested 6.41 billion, 4.94 billion, and 5.92 billion in R&D activities in the years 2017, 2016, and 2015, respectively. In order to maintain its leadership position in the market, the company focuses on growth strategies such as partnerships and expansions. The company is adopting new strategies and developing and expanding its product range. It also focuses on collaborations, agreements, acquisitions, and approvals in order to meet the rising market demand. For instance, in November 2019,Bristol-Myers Squibb acquired Celgene, C a leading biopharma company. This acquisition helped BMS to further progress relating to the patent estate for REVLIMID, the US Food and Drug Administration (FDA) approval of INREBIC (fedratinib) for the treatment of certain forms of myelofibrosis, the US FDA approval of REBLOZYL (luspatercept-aamt) for the treatment of anaemia in certain adult patients with beta thalassemia, and regulatory filings of luspatercept and ozanimod in the US and Europe. Eli Lilly (US) is one of the leading players in the global API market. The company invests significantlyin research &development in order to sustain its competitiveness. For instance, in 2017, the company invested USD 5.3 billion in R&D activities. Through Kinsale Manufacturing, it develops, manufactures, and supplies APIs. The company manufactures small molecule APIs along with APIs for biopharmaceutical medicines. Eli Lilly’s human pharmaceutical research focuses on cancer, diabetes, neurodegeneration, immunology, and pain. In order to influence growth opportunities in the global API market, the company emphasizes on adopting organic as well as inorganic growth strategies. For example, in February 2020, Eli Lilly completedthe acquisition of Dermira, a leading biopharmaceutical company specializing in dermatology. This acquisitionenables the expansion of Lilly's portfolio of marketed dermatology medicines with the addition of QBREXZA (glycopyrronium), a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating).

3. Buy https://www.360quadrants.com/quadrant-report/active-pharmaceutical-ingredient-(api)/buy- now?reporttype=corporates_license_price Active Pharmaceutical Ingredient Competitive evaluation Report 360QUADRANTS COMPANY EVALUATION METHODOLOGY The top Active Pharmaceutical Ingredient Competitive evaluation performed using the following methodology: 1.A highly experienced team of researchers and senior analysts conducts extensive research to generate a list of vendors (competitors). 2.A patent-pending algorithm is used to collect inputs from key stakeholders—industry experts, buyers, vendors, and 360Quadrants analysts—based on criteria for Product Maturity and Company Maturity. a.Criteria under Product Maturity include breadth and depth of product/service offering, product features and functionalities, product differentiation, and their impact on customer value. b.Criteria under Company Maturity include geographical footprint, partner ecosystem, financial stability, and client coverage or sector footprint. 3.Approximately 30+ in-depth parameters will be considered for research into the Active Pharmaceutical Ingredient market. These parameters will be updated every six months to ensure the latest developments are taken into consideration. 4.A weight is assigned to each stakeholder based on information gathered pertaining to the above criteria as well as inputs from stakeholders. These inputs follow the order of priority given below: a.Buyers b.Industry Experts c.360Quadrants Analysts d.Vendors (Competitors) 5.The inputs are analyzed, and a final rating is assigned to each vendor (competitor). 6.After the finalization of ratings, each vendor is placed in the most relevant quadrant based on its score. ABOUT 360QUADRANTS 360Quadrants is the largest marketplace looking to disrupt US $6.3 trillion of technology spends and is the only rating platform for vendors in the technology space. The platform provides users access to unbiased information that helps them make qualified business decisions. The platform facilitates deeper insight using direct engagement with 650+ industry experts and analysts and allows buyers to discuss their requirements with 7500 vendors. Companies get to win ideal new customers, customize their quadrants, decide key parameters, and position themselves strategically in a niche space, to be consumed by giants and startups alike. Experts get to grow their brand and increase their thought leadership. The platform targets the building of a social network that links industry experts with companies worldwide. The platform has around 400 total buyers across various markets.

4. 360Quadrants will also be launching quadrants in fields like Digital Transformation Software, Cloud Computing Software, and Access Control Software. Access Full Report @:- https://www.360quadrants.com/quadrant-report/active-pharmaceutical- ingredient-(api)/buy-now?reporttype=corporates_license_price